0001553878-17-000009.txt : 20170203 0001553878-17-000009.hdr.sgml : 20170203 20170203163258 ACCESSION NUMBER: 0001553878-17-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170201 FILED AS OF DATE: 20170203 DATE AS OF CHANGE: 20170203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHARP PHILIP A CENTRAL INDEX KEY: 0001226295 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 17572573 MAIL ADDRESS: STREET 1: BIOGEN INC LEGAL DEPARTMENT STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2017-02-01 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001226295 SHARP PHILIP A 300 THIRD STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2017-02-01 4 M 0 25000 31.29 A 165795 D Common Stock 2017-02-01 4 S 0 20171 39.72 D 145624 D Common Stock 2017-02-01 4 S 0 4829 40.16 D 140795 D Common Stock 126104 I by Trust Stock Option (right to buy) 31.29 2017-02-01 4 M 0 25000 0.0 D 2008-12-12 2017-12-13 Common Stock 25000 0 D The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Sale prices ranged from $39.09 to $40.08 Sale prices ranged from $40.10 to $40.24 The 126,104 shares reported as indirectly owned by trust include: (i) 94,838 shares in the Phillip A. Sharp 2009 Grantor Annuity Trust No. 3, and (ii) 31,266 shares in the Phillip A. Sharp 2008 Grantor Annuity Trust No. 2 (which include shares distributed from the 2010 Trust). By: /s/ Michael P. Mason, Attorney-in-Fact For: Phillip A. Sharp 2017-02-03